Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Leona Rudinskas"'
Autor:
Stefan Glück, Ralph M. Meyer, Stephen Couban, Leona Rudinskas, Michael Crump, Sarah Matthews, Andrew Maksymiuk, Brent W. Zanke, Elizabeth Eisenhauer, Paul Hoskins
Publikováno v:
Leukemia & Lymphoma. 43:1581-1587
Preliminary results indicate that inhibitors of the nuclear enzyme topoisomerase (topo) I, such as topotecan, may be active in non-Hodgkin's lymphoma (NHL). Pre-clinical studies have shown sequential administration of a topo I and II inhibitor has su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b150839226432c45f14b9646b174c0d2
https://doi.org/10.1080/1042819021000002901
https://doi.org/10.1080/1042819021000002901
Autor:
Marina Djurfeldt, Keyue Ding, Michael J. Kovacs, Linda M. Vickars, Chaim Shustik, Ralph M. Meyer, Dolores A. Sicheri, Kulwant Gill, Lois E. Shepherd, Sue Robinson, Leona Rudinskas, Jonathan Wilson, Robert M. Barr, Sean Dolan, David Walde, Kuljit Grewal, Andrew Belch, Kenneth S. Wilson, Sheldon H. Rubin
Publikováno v:
British journal of haematology. 136(2)
Summary The effectiveness of melphalan plus dexamethasone (M-Dex) with melphalan plus prednisone (MP) as induction therapy and dexamethasone with observation as maintenance therapy was compared in 585 older patients with multiple myeloma. Randomizati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9046950b44288bd05095172af17a2a0
https://pubmed.ncbi.nlm.nih.gov/17233817
https://pubmed.ncbi.nlm.nih.gov/17233817
Autor:
Frances A. Shepherd, Y.H. Rahim, J. Dancey, Glenwood D. Goss, P.G. Lopez, Gregory R. Pond, J.F. Pouliot, A. Rodgers, Leona Rudinskas, Natasha B. Leighl, Ronald Burkes
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 52(3)
Summary Background Despite chemotherapy and radiotherapy for small cell lung cancer (SCLC), most patients die within 2 years. Response rates for second-line chemotherapy are 15–25%, with a median survival of 5 months. Caelyx, a pegylated liposomal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d01dc2daaf42a003b5c9c4d0deae25b6
https://pubmed.ncbi.nlm.nih.gov/16597474
https://pubmed.ncbi.nlm.nih.gov/16597474
Autor:
Brian Patrick Higgins, Yasmin H. Rahim, Leona Rudinskas, A. Rodgers, Natasha B. Leighl, P.L. David Walde, Pedro G. Lopez, Ronald L. Burkes, Frances A. Shepherd, Gregory R. Pond, J. Dancey
Publikováno v:
Clinical lung cancer. 5(2)
The purpose of this study was to determine the recommended phase II dose of liposomal doxorubicin (Caelyx™; Doxil® in the United States) in combination with cyclophosphamide and vincristine for previously treated patients with good performance sta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13fe998ec9e6753a5acd4c5e99f405c8
https://pubmed.ncbi.nlm.nih.gov/14596693
https://pubmed.ncbi.nlm.nih.gov/14596693
Autor:
Paul Goss, Ronald Burkes, Leona Rudinskas, Michael King, Winston Chow, Robert Myers, Murray Davidson, Peeter Poldre, Michael Crump, David Sutton, Gerald Scott
Publikováno v:
Leukemialymphoma. 18(1-2)
This phase II study was designed to improve the outcome of elderly patients with advanced aggressive non-Hodgkin's lymphomas (NHL's) by employing a novel chemotherapy regimen PEN (prednisone, oral etoposide and mitoxantrone), as initial treatment. Be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::053e14398da8bff5eff8daf61ffc44ee
https://pubmed.ncbi.nlm.nih.gov/8580817
https://pubmed.ncbi.nlm.nih.gov/8580817